Skip to content
Menu

JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $80

Benzinga Newsdesk 19 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $82 to $80.

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $82 to $80.

Read at benzinga.com